SECRETARY, DEPARTMENT OF PHARMA,GOVT. OF INDIA INDO AFRICA BUSINESS SUMMIT AT HYDERABAD
|
|
- Aubrie Small
- 6 years ago
- Views:
Transcription
1 *ADDRESS BY SHRI ASHOK KUMAR, IAS, SECRETARY, DEPARTMENT OF PHARMA,GOVT. OF INDIA INDO AFRICA BUSINESS SUMMIT AT HYDERABAD Shri Anand Sharmaji, Hon ble Minister of Commerce & Industry, Govt. of India, Prof. Mr. Peter A Nyongo, Hon ble Minister for Medical Services, Govt. of Kenya, Mr. Venkat Jasti, Chairman, Pharmexcil, Director Generals of FDA from all countries, Foreign dignitaries, my colleagues from the Commerce Department and Department of Pharmaceuticals, Government of India, ladies and gentlemen. Indian Pharmaceutical industry has performed extremely well during the period with exports of around Rs crores (approx. US$9.00 bln.). This is a year on year (YoY) growth of 21.98% (21.33% in US$ terms) compared with 8.34% during when exports are valued at Rs. 30, crores (revised) (US$7.64bn.). During last year, the sector contributed 6.1% of the country s total merchandise exports, up from 4.69% during the year of The sector ranked 5 th (for 5 years from to excepting for when it ranked 4 th ) among the 92 principal commodities only behind Petroleum & crude products, Gems & Jewellery, Transport Equipment and 1
2 Machinery & Instruments. The Indian pharmaceutical Market size of industry (excluding exports and public procurement) at retail value, as per ORG-IMS reports stood at Rs.55,454 crores. (approx. US$12.2bn.) against Rs.50,410 crores in (US$11.08bn.) growing by a healthy 10% year on year. The industry achieved this feat in the face of global financial recession and slow down in India s GDP. It may be noted that as per the revised estimates of Ministry of Statistics & Program Implementation (MOSPI), India s GDP at constant prices (at factor cost) grew at 6.7% during (compared with 9% during previous year) when manufacturing industry grew by a meager 2.4% compared with previous year s growth rate of 8.2%. During the period Apr to Feb for which data is available from DGCI&S, India continues to exports predominantly formulations (58%), followed by Bulk Drugs (40%) and Herbals. United States of America is the top export destination with a share of 18% in India s pharmaceutical exports valued at US$1.55bn. followed by Russia valued at US$0.33bn. with a share of 3.84%, Germany (US$.31bn. and 3.65%), Austria (US$0.31bn. and 3.58%) and UK (US$0.27bn. and 3.12%). 2
3 India s success in global markets and strengths in R&D capabilities can best be gauged by the number of product & API approvals received from various regulatory authorities. India, as at the end of 2008, accounts for one out of every four Abbreviated New Drug Application (ANDA) approvals in the years 2007 & 2008, ranks first in total Type II active Drug Master Files (DMFs) with U.S. FDA and it also received 31% of all tentative approvals. Over 30% of DMFs, ANDAs, Tentative Approvals in USA are from India. The country Ranks first in total Type II active Drug Master Files (DMFs) with U.S. FDA and received 31% of all tentative approvals. India has filed DMFs for a total of 462 molecules of the total 1,117 molecules filed with US FDA. These DMFs have been filed from a total of 169 facilities by a total 136 Indian companies. India has 793 WHO cgmp approved pharmaceutical plants, 153 EDQM (for 195 molecules out of the total 693 molecules) approved pharmaceutical manufacturing facilities among which 49 sites have CEP approvals. It has the highest number of Certificate of Suitability (CEPs) is granted to India (461 CEPs (19.78%) of the total 2,330 granted by EDQM) as at the end of
4 India has several opportunities for Indian Pharmaceutical Industry. An estimated US$103 billion of generic products are at risk of losing patents by Even at a conservative estimate of 15% opportunity this translates into US$18.4 billion opportunity for India. With around 200 companies, India's biotechnology sector is growing fast and is in the early stages of development with initial emphasis on vaccines and bio-services. IMS estimates that biotechnology products accounted for over 10 percent of global pharmaceutical sales, 20 Patents on the first generation of blockbuster biopharmaceuticals are beginning to expire. Sales of bio-generics are flourishing in the unregulated markets. Firms based in India and China could be among the successful firms to bring bio-generics to the regulated markets very soon. The global market for contract manufacturing of prescription drugs is estimated to increase from a value of $26.2 billion to $43.9 billion. India and China could potentially account for 35 percent to 40 percent of the outsourced market share for active pharmaceutical ingredients, finished dosage formulations and intermediates. India has very high skills in Phase II & Phase II Clinical trials, and has good to high skills in Preclinical trials and Phase I clinical trials. 4
5 Contract research in generic pharmaceuticals is also a significant opportunity. Established generic companies would like to outsource or buy services in formulation development, bioequivalence testing, stability studies centers, etc. Various surveys indicate that India has quite a number of resourceful firms in the field of Chemistry providing high quality output in timely schedules, allowing more leads to pursue. India is significantly ahead in chemistry services such as analog preparation, analytical chemistry, focus library, combinatorial chemistry, structural chemistry, structural drug design, computer aided drug design, high throughput screening and assay development. There are opportunities such as Licensing deals with MNCs for New Chemical Entities and new drug delivery systems, marketing alliances for MNC products in domestic and international markets, Contract manufacturing arrangements with MNCs, Potential for developing India as a centre for international clinical trials. The country has the potential to become a niche player in global pharmaceutical R&D and possibilities for expansion of Biotechnology generics (also known as bio-similars) and Biopharmaceuticals. 5
6 It is in this context, the role of India is poised to become manufacturing hub for global pharmaceutical industry and as a supplier of affordable quality pharmaceuticals especially to third world countries. The country is increasingly becoming an important source of generic medicine in view of its rich vendor base. Indian Pharmaceutical Sector has come a long way, being almost non-existing during 1970 to a prominent provider of health care products; meeting almost 95% of country s Pharmaceutical needs. The Indian Pharma industry has been consistently charting high growth rate in the 1990s and 2000s. India is a member/signatory to TRIPS (1995), Paris Convention (1998), Convention on Bio-diversity (1994) and many others. India fulfilled the WTO commitment and our Patent s (Amendment) Act 2005 has become TRIPS compliant since 1 st January India thus joined the countries having industrialized free market economies and started with Product Patent Regime. Ladies and Gentlemen, let me inform you that the trend of patent filing in India has increased tremendously and it is understood that a total of more than 35,000, out of which more than
7 patent applications have been received from foreign applicants during the last fiscal. Ladies and gentlemen, while this is trend is reflection of a good sign for development, but I would like to inform you that we are also aware of the importance of taking steps to safeguard the sanctity of our Patent system and prevent filing and grant of frivolous unpatentable subject matters. Let me also alert all our friends from African continent that IP related issues are being used against India to create trade barriers & keep us out of race in the competition. Let me alert my friends here about the efforts made by certain vested interests in blocking the affordable Indian Generics from reaching the poorest of the poor. Examples of cross border seizures of essential drugs in the European Union especially when the drugs / APIs exported from India do have patents filed or grant either in the originating country (i.e. India) or the importing country. In one of the seizures the anti-aids drugs were being imported Clinton Foundation from India and meant for Nigeria were detained in Netherlands on the grounds of alleged patent violation. 7
8 Ladies and Gentlemen: let me elucidate with an example I have personally witnessed during our participation at CPhI exhibition at Germany. We were witness to the barge of legal practitioners literally visiting each and every Indian stall & informing them that they had displayed products that were infringing the rights of the patent holders. It was explained to them that the products displayed in the exhibition were not for sale in the country and was meant for the visitors from other countries visiting the exhibition where they were not patented. Despite the pleas from our Indian Participants the legal practitioners persisted in threatening the Indian participants in the Exhibition with penal action, arrests, legal action etc and also coercing them to compound the offence by seeking huge amount as compounding fees for them not resorting to legal action. Therefore, ladies & gentlemen, the Department of Pharmaceuticals, Government of India decided to assist the Indian participants through PHARMEXCIL in future exhibitions in providing legal assistance at all such exhibitions to legally deal with cases on the spot and support the MSME sector financially also. 8
9 Ladies & gentlemen, I am glad to inform you that Department of Pharma, Government of India by funding through Pharmexcil has also initiated IP awareness programmes to educate the MSME Sector and a series of such programme are being conducted in major cities. Being aware of the likely problems to be faced by the Pharma Industry on IP related problems especially the MSME Sector, my department through Pharmexcil started IPR cell at their Head Office at Hyderabad and one more is likely to be commissioned shortly at NIPER, Mohali at Chandigarh. Lastly, I would like to stress that the Government of India will assist the Pharmaceutical Industry in all possible manner in making India a Global player and achieve the goal of Health for all and reaching the poorest of the poor around the world. With these few words, I would not like to take much of your time and I wish you all the best in your deliberations for the next two days. Jai Hind *Shri Ashok Kumar could not attend the inaugural function/event due to flight delay and a copy is reproduced. 9
4. Pharmaceuticals Sector and Opportunity Ahead
4. Pharmaceuticals Sector and Opportunity Ahead In general, there are several reasons which justify focusing on pharmaceutical exports. The most important of these reasons is the size of the industry,
More informationTable of Contents. 1. Pharmaceutical Market of Syria India s Bilateral Trade with Syria... 3
PHARMACEUTICALS EXPORT PROMOTION COUNCIL 101, Aditya Trade Center, Ameerpet, Hyderabad 500 038 Phone: 040 23735462/66, Fax: 040 23735464 E mail: info@pharmexcil.com; website: www.pharmexcil.com Status
More informationNew Man International Journal of Multidisciplinary Studies (ISSN: ) Mohd Azhar-Ud-Din Malik Research Scholars Jiwaji Unversity Gwalior (M.
Abstract 8. INDIAN PHARMACEUTICAL INDUSTRIAL CONTRIBUTION AND COMPETITION Mohd Azhar-Ud-Din Malik Research Scholars Jiwaji Unversity Gwalior (M.P) Biotechnology has become a source of earning for many
More informationGlossary of Abbreviations
Glossary of Abbreviations ANDA APhA Abbreviated New Drug Application American Pharmaceutical Association API Active Pharmaceutical Ingredient BA/BE Bioavailability/Bioequivalence BE Bioequivalence Bio
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationIMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU. IPA/EDQM/WHO 2012, Mumbai
IMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU from the perspective of Indian manufacturers and Indian authorities IPA/EDQM/WHO 2012, Mumbai S.M.MUDDA Micro Labs Limited, Bangalore
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationPHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)
PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) COPY Date : 23-02-2010 News / Story reproduced with thanks:- Stockmarkest.com Indian pharmaceutical industry has
More informationIP, LOCAL MANUFACTURING, INDUSTRIAL AND ACCESS POLICIES
IP, LOCAL MANUFACTURING, INDUSTRIAL AND ACCESS POLICIES Prof Frederick Abbott FSU College of Law, USA UNDP and WHO Consultant CONSULTATIVE FRAMEWORK FOR INTELLECTUAL PROPERTY IN SOUTH AFRICA 28-30 September
More informationIndia Pharma Summit
Department of Pharmaceutical Ministry of Chemicals & Fertilizers Government of India India Pharma Summit 2013-14 Enhancing India's Global Role in Supply of Generic Medicines Focus on Strengening Domestic
More informationDynamics of Drug Master Filings at United States Food and Drug Administration
Dynamics of Drug Master Filings at United States Food and Drug Administration Rau. B. S 1 Appaji P. V 2 Abstract: Drug master filing at USFDA in one of the parameters that helps in knowing the potentiality
More informationKorea GMP & DMF. April Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon
Korea GMP & DMF April. 2015 Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon Contents 1. KPTA 2. Pharmaceutical industry 3. KGMP 4. KDMF KPTA KPTA Purpose ㅇ Trade promotion of pharmaceuticals,
More informationISPUB.COM. Opportunities for Generic Drugs in India. P Sharma, S Kumar, R Pahwa, A Sharma INTRODUCTION BRANDED DRUG GENERIC DRUG
ISPUB.COM The Internet Journal of Third World Medicine Volume 8 Number 1 P Sharma, S Kumar, R Pahwa, A Sharma Citation P Sharma, S Kumar, R Pahwa, A Sharma.. The Internet Journal of Third World Medicine.
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationCERTIFICATE IN BIOPHARMACEUTICALS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers
More informationCHAPTER 3 INDIAN PHARMACEUTICAL MARKET AT A GLANCE. The Indian pharmaceutical industry ranks among the top five countries by
CHAPTER 3 INDIAN PHARMACEUTICAL MARKET AT A GLANCE 3.1 INTRODUCTION The Indian pharmaceutical industry ranks among the top five countries by volume (production) and accounts for about 10% of global production.
More informationPHARMA MARKET REPORT- UGANADA
PHARMA MARKET REPORT- UGANADA PHARMEXCIL Hyderabad Contents DEMOGRAPHY...1 Introduction...2 Latest Updates...3 Strengths...3 Weaknesses...3 Opportunities...3 Market...3 Regulations:...4 Epidemiology...4
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationRegulatory requirements and registration process of Generic Drugs in China
13 Regulatory requirements and registration process of Generic Drugs in China Jitendra Kumar Badjatya Deputy Manager-DRA, Montajat Pharmaceutical Company Limited, Dammam, KSA jeetbadjatya@gmail.com ABSTRACT
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationINDO AFRICA PHARMA MEET 24-27TH SEPT, Hotel Marriot Hussain Sagar Lane, Road, Hyderabad India SPONSORED BY PHARMEXCIL
INDO AFRICA PHARMA MEET 24-27TH SEPT, 2009 Hotel Marriot Hussain Sagar Lane, Road, Hyderabad India SPONSORED BY PHARMEXCIL Drug Registration procedures in Tanzania Nditonda B. Chukilizo and Adonis Bitegeko
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationSTRATEGIES FOR INTEGRATING SUPPLY CHAIN IN NEW PRODUCT DEVELOPMENT OF GENERIC PHARMACEUTICAL COMPANIES: A STUDY
Inspira- Journal of Modern Management & Entrepreneurship (JMME) 51 ISSN : 2231 167X, General Impact Factor : 2.5442, Volume 08, No. 02, April, 2018, pp. 51-57 STRATEGIES FOR INTEGRATING SUPPLY CHAIN IN
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION About us. Established in 1973, Micro Labs is a fully integrated pharmaceutical company, present across the entire pharmaceutical value chain from Research and Development, Active
More informationInt. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
More informationRating criteria for the pharmaceuticals industry. February 2018
Rating criteria for the pharmaceuticals industry February 2018 Criteria contacts Pawan Agrawal Chief Analytical Officer CRISIL Ratings Email: pawan.agrawal@crisil.com Ramesh Karunakaran Director Rating
More informationFuture Prospects and Barriers of Pharmaceutical Industries in Bangladesh
Bangladesh Pharmaceutical Journal 19(1): 53-57, 2016 Future Prospects and Barriers of Pharmaceutical Industries in Bangladesh Jesmin Sultana Department of Business Administration, University of Asia Pacific,
More informationPharma & Food Packaging Conclave
6 July, 2012 Novotel Convention Centre Hyderabad Pharma & Food Packaging Conclave Exclusive Panel Discussion on Reducing Risk and Achieving Strategic Business Goals in Pharma and Food Manufacturing. Featuring
More informationRampant evergreening in Indian pharma industry
Rampant evergreening in Indian pharma industry Accessible and affordable medicines are of utmost importance for any needy patient. In a developing country like India and many of its counterparts, generic
More informationLife Sciences. Key issues for senior life sciences executives. Pharmaceutical patents in Canada: key issues for life sciences companies
Life Sciences 2017 Key issues for senior life sciences executives Pharmaceutical patents in Canada: key issues for life sciences companies Yoon Kang and Daphne Lainson Smart & Biggar/Fetherstonhaugh Innovative
More informationPharmaceutical Ingredients - Trends & Enforcement Issues
Pharmaceutical Ingredients - Trends & Enforcement Issues Dr. Arnulf Heubner Member of the Board Chairman Pharmaceutical Business Committee 27th-29th April, 2008 Dublin, Ireland 1 Agenda EC Regulatory Objectives
More informationIndia s Export Performance Analysis An Analysis
India s Export Performance Analysis An Analysis Rashmi Taneja Assistant Professor, Shri Aurobindo College, University of Delhi, Delhi Abstract Merchandise exports from India have exhibited a perceptible
More informationBusiness Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs
Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where
More informationIndia An Insight Into The Changed Patent Regime & Protecting Your Pharmaceutical IP
India An Insight Into The Changed Patent Regime & Protecting Your Pharmaceutical IP Chid S. Iyer, SUGHRUE MION, PLLC, Washington DC ciyer@sughrue.com V. Lakshmikumaran Lakshmikumaran, LAKSHMIKUMARAN &
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationCompany Research. Dr Reddy s Laboratories- BUY with a Target of Rs 1,962. Investment overview- Business Overview-
Date-16-07-2012 Dr Reddy s Laboratories- BUY with a Target of Rs 1,962 Investment overview- Shareholders Information Global Generics grew by 68% to Rs 70,243mn in FY12 from Rs 53,340mn in Fy11. Therefore
More informationCollaborative Procedure to Accelerate Medicines Registration
Collaborative Procedure to Accelerate Medicines Registration Pharmaceuticals Limited Mumbai, INDIA Challenging the Frontiers in Healthcare Outline Introduction to Macleods Pharma. Regulatory filings by
More informationUnderstanding How The Indian Pharmaceutical Industry Works Part 3
Understanding How The Indian Pharmaceutical Industry Works Part 3 Key Performance Indicators Pharmaceutical Sector Sales & Marketing Marketing always starts with the customer and ends with the customer
More informationPatricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, (732)
Pharmaceutical Technology Patricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, pvanarnum@advanstar.com, (732) 346-3072 Biopharmaceutical Industry in 2012: Optimism on the Rise
More informationICH Q10/WHO TRS A Regulatory Perspective
Presentation by: Dr. A. Ramkishan Asst. Drugs Controller (India) Govt. of India ICH Q10/WHO TRS A Regulatory Perspective Contents of Presentation Introduction History of WHO GMP TRS guidelines A Unique
More informationA Comparative Study of Profitability of Selected Pharma Companies of India
A Comparative Study of Profitability of Selected Pharma Companies of India Dr.Bhavik U.Swadia 1 1 Assistant Professor, S.M.Patel Institute of Commerce, GLS University, India Correspondence: Dr.Bhavik U.Swadia,
More informationIndian CRAMS players to cram in growth: CARE Ratings
January, 2015 Credit Perspective : Indian CRAMS Indian CRAMS players to cram in growth: CARE Ratings CARE Ratings expects Indian Contract Research and Manufacturing Services (CRAMS) players to register
More informationCHAPTER THE PHARMA LEGAL HANDBOOK SOUTH AFRICA
CHAPTER THE PHARMA LEGAL HANDBOOK SOUTH AFRICA THE PHARMA LEGAL HANDBOOK ANSWERS ESSENTIAL QUESTIONS ABOUT THE LEGAL AND REGULATORY ENVIRONMENT FOR PHARMACEUTICALS IN SOUTH AFRICA. IT IS A MUST-HAVE FOR
More informationCompany, Position & Person Profile. Cadila Healthcare Limited
Company, Position & Person Profile Cadila Healthcare Limited About Zydus Cadila Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain.
More information2018 Wells Fargo Healthcare Conference
2018 Wells Fargo Healthcare Conference September 5, 2018 Shawn Cavanagh Executive VP & COO Forward-Looking Statements & Non-GAAP Financial Measures Statements in this presentation regarding the future
More informationGrowth and Structure of India s Foreign Trade in the Post-reform Period
Growth and Structure of India s Foreign Trade in the Post-reform Period (T. Maheswari, Assistant Professor of Economics, Thiagarajar College, Madurai, Tamil Nadu) Introduction Foreign Trade has been one
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)51 DAF/COMP/GF/WD(2014)51 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Feb-2014 English
More informationDr. Reddy s at a glance
Dr. Reddy s at a glance 22000 people 40 nationalities 200 products 30 countries One Purpose We accelerate access to affordable and innovative medicines because Dr. Reddy s at a glance 8/22/2017 2 Our Purpose
More informationPortfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO
Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated
More informationWelcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese
More informationCurrent Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V
Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V Abstract: Indian pharmaceutical industry has proved manufacture of global quality pharmaceutical products
More informationContact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , ,
Topics Covered: MODULE 1 Introduction To Pharmacovigilance Terminologies used in Pharmacovigilance ADRs Polypharmacy MODULE 2 Pharmacoepidemiology Iatrogenesis Prescription-event monitoring MODULE 3 SAE
More information(MPY-201 DRA) - ADVANCE DRA I
(MPY-201 DRA) - ADVANCE DRA I (Indian Legislation) The Drugs and Cosmetics act, 1940 and Rules with emphasis on Good laboratory practices and requirements of premises and equipments (Schedule L-I), Good
More informationAn application for a license to market a generic (or a duplicate) version of a drug that has already been granted an approval under a full NDA.
ANDA REQUIREMENTS 1 Abbreviated New Drug Application (ANDA) An application for a license to market a generic (or a duplicate) version of a drug that has already been granted an approval under a full NDA.
More informationIPRs in the pharmaceutical industry
IPRs in the pharmaceutical industry The Development Implications of Intellectual Property Rights and TRIPS Washington, DC, June 4-5, 2008 CARSTEN FINK Overview The structure of the pharmaceutical industry
More informationPress Conference APIs Update
Press Conference APIs Update CPhI Frankfurt 30th September 2008 Guy Villax Member of the EFCG Board CEO of Hovione, Portugal BUQ/SL 20070222 13:30 hrs Pharmaceuticals Business Committee Agenda API GMP
More informationPharmaceuticals in a Global Environment
Pharmaceuticals in a Global Environment The Story of Heartburn Anne Johnson, M.D. 100 University Dr. Long Beach, CA 90840 Lic No: 1234 DEA #: 98765 The Purple Pill Prilosec, 20 mg As needed for acid reflux
More informationResearch & Reviews: Journal of Hospital and Clinical Pharmacy
Research & Reviews: Journal of Hospital and Clinical Pharmacy Challenges Faced by MNCs in Pakistan Due to Unethical Practice of National Pharmaceuticals Industry Yasir Mehmood * Faculty of Pharmacy University
More information8. Fostering Indian Clinical Trials Industry. 8.1 Clinical Trials Opportunity. Strategy for Increasing Exports of Pharmaceutical Products
8. Fostering Indian Clinical Trials Industry 8.1 Clinical Trials Opportunity India has significant valid population to participate in clinical trials and the country also has proven capabilities in medical
More informationDr. Reddy s. Investor Presentation Dr. Reddy s Laboratories Limited Hyderabad, India NYSE: RDY
Dr. Reddy s Investor Presentation 2015 Dr. Reddy s Laboratories Limited Hyderabad, India NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and information that involve
More informationComparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan
Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan The International Economic Forum of the Americas Serge Lapointe, Ph.D. Partner, Patent Agent June
More informationIntroduction of service items
Introduction of service items Member Payment Chart Fee (Yuan RMB) Service Item Chinese Herbal Medicine Elementary: 1800;Middle: 3800; Senior: 5800;VIP:8800 Pharmaceutical Raw Materials 4900 Industry s
More informationAfrica 2015 Prospects, Challenges and Opportunities. Haleh Bridi Director of External Relations and Partnership Africa Region, World Bank
Africa 2015 Prospects, Challenges and Opportunities Haleh Bridi Director of External Relations and Partnership Africa Region, World Bank Africa continues to grow Despite a weak global economy, growth in
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More informationA STUDY ON VARIATIONS IN PHARMACEUTICAL PRODUCTS IN PHILIPPINES AND VARITAION POLICIES IN US, CANADA, AUSTRALIA
ISSN: 2230-7346 Jignesh Shah et al. / JGTPS / 6(1)-(2015) 2340 2344 (Review Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com A STUDY ON VARIATIONS IN PHARMACEUTICAL
More informationPHD Research Bureau 1
PHD Research Bureau 1 India s Exports Diversification Crisscross Outcomes Executive Summary India s diversification of export markets has been increased as concentration of exports towards the top 10 export
More information2018 EDITORIAL COVERAGE. Connecting the Pharma Industry for 28 Years.
2018 EDITORIAL COVERAGE Connecting the Pharma Industry for 28 Years EDITORIAL COVERAGE: EXPERT INSIGHT AND ANALYSIS Pharmaceutical Technology Europe sets the standard for publishing independent, industry-leading
More informationAsian Gas Summit 2013 December 3, Asia driving natural gas growth
IGU Asian Gas Summit 2013 December 3, 2013 Asia driving natural gas growth Jérôme Ferrier President IGU Allocated time: 30 minutes Dr. Manmohan Singh, Hon ble Prime Minister of India Shri S. Jaipal Reddy,
More informationThe pessimist sees difficulty in every opportunity, the optimist sees the opportunity in every difficulty. Churchill, Winston
The pessimist sees difficulty in every opportunity, the optimist sees the opportunity in every difficulty. Churchill, Winston Expectations are same: Safety Efficicacy GMP compliance Profile attribute Population
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationManagement Team. Over 35 years experience in the pharmaceuticals industry
2017 1 Overview Located in Bangalore, a Dedicated cgmp and cglp Compliance Laboratory Established in September 2010 Approved Contract research Organization by India FDA Approved by Health Canada since
More informationASCENDIA PHARMACEUTICALS Aspiring for Better Medicine
ASCENDIA PHARMACEUTICALS Aspiring for Better Medicine Ascendia Pharmaceuticals, founded in 2012, is a privately-owned, speciality pharmaceutical company dedicated to developing enhanced formulations of
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationSOUTH AFRICA ITALY SUMMIT 014
SOUTH AFRICA ITALY SUMMIT 014 SOUTH AFRICA AND ITALY RELATIONS IN THE CURRENT GEOPOLITICAL AND ECONOMIC SCENARIO PROFESSOR MTHULI NCUBE BLAVATNIK SCHOOL OF GOVERNMENT UNIVERSITY OF OXFORD OCTOBER 2, 2014
More informationRussian Federation. Chapter 12. By Julianna Tabastajewa and Svetlana Rudevich
Chapter 12 Russian Federation By Julianna Tabastajewa and Svetlana Rudevich Legal System The Russian Federation is a federal state consisting of a total of 83 republics, regions, federal cities, autonomous
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationPHARMACEUTICAL INDUSTRY AND COMPLIANCE. Whitepaper
PHARMACEUTICAL INDUSTRY AND COMPLIANCE Whitepaper Table of Contents Introduction... 2 Compliance: A Critical Consideration... 3 Highly Regulated Environment... 4 Manufacturing Execution Systems (MES)...
More informationCHINA. Australia - China Life Science Summit. . Bio & Pharma Logistics
CHINA. Bio & Pharma Logistics Andrew McDonald Operations Director, Asia Pacific Melbourne, Australia, 27th March 2013 Australia - China Life Science Summit Responsibilities Who takes responsibility on
More informationAnalysis of Indian engineering exports for April May, 2017
Analysis of Indian engineering exports for April 2017 22 May, 2017 India s Merchandise Trade scenario April 2017 India's merchandise export achieved double-digit growth for the third straight month to
More informationNOTABLE ACHIEVEMENTS AND INITIATIVES TAKEN BY THE CENTRAL DRUGS STANDARD CONTROL ORGANIZATION IN THE YEAR 2014
NOTABLE ACHIEVEMENTS AND INITIATIVES TAKEN BY THE CENTRAL DRUGS STANDARD CONTROL ORGANIZATION IN THE YEAR 2014 1. STRENGTHENING OF CDSCO i. Manpower strengthening CDSCO is being progressively strengthened.
More informationPresentation before CIPIH of the WHO
Presentation before CIPIH of the WHO By Yogin Majmudar President INDIAN DRUG MANUFACTURERS ASSOCIATION New Delhi 4 November 2004 4 November 2004 1 Progress of Pharma Industry in India 1911: The Indian
More informationPHARMACEUTICAL AND BIOTECHNOLOGY UPDATE
Pharmaceutical and Biotechnology Update April 22, 2009 1 Hogan & Hartson LLP PHARMACEUTICAL AND BIOTECHNOLOGY UPDATE Current Trends in FDA s Pharmaceutical Good Manufacturing Practice (GMP) Warning Letters
More informationPHARMACEUTICAL AND BIOTECHNOLOGY UPDATE
Pharmaceutical and Biotechnology Update April 22, 2009 1 Hogan & Hartson LLP PHARMACEUTICAL AND BIOTECHNOLOGY UPDATE Current Trends in FDA s Pharmaceutical Good Manufacturing Practice (GMP) Warning Letters
More informationPolicies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More informationPlastics Processing Machinery (PPM) Overview
Plastics Processing Machinery (PPM) Overview Plastics Machinery Market is Approx Rs. 4,000 Crores. Domestic production is Approx Rs. 2,400 Crores. Sector employs approx 1.20 Lakh (Direct + Indirect) people
More informationChallenges and Opportunities of Global Value Chains in the Context of SMEs
Challenges and Opportunities of Global Value Chains in the Context of SMEs National Consultation on SDGs Industrialisation and Employment for Sustainable Growth in India 2-3 rd August 2016, New Delhi Pranav
More informationTogether, beyond the standard. Reference standards and services for the pharmaceutical industry. lgcstandards.com/mikromol
Together, beyond the standard. Reference and services for the pharmaceutical industry QUALITY IS 9001 IS/IEC 17025 IS 17034 GMP lgc.com/mikromol Welcome to Mikromol 25 years of excellence At Mikromol,
More informationChapter - 1 ABSTRACT. The pharmaceutical industry in India had a very humble beginning & has now come a
Chapter - 1 ABSTRACT 1.1 INTRODUCTION 1.1.1 Indian Pharmaceutical Industry The pharmaceutical industry in India had a very humble beginning & has now come a long way. The turnover of the pharmaceutical
More informationRasha Sayed Salama, MD, PhD, UAE
GaBI Scientific Meetings 10 October 2018, Le Meridien Dubai, United Arab Emirates 2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars
More informationTable of Contents. Welcome to Dishman. Our Mission. Our Focus: Client Satisfaction
Welcome to Dishman Our Mission Dishman Group continually invests in the global pharmaceutical industry, ensuring Dishman s business can provide pharmaceutical customers with high-value, high-quality products
More information2.0 RESEARCH METHODOLOGY. U.S. has a lion s share in the global pharmaceutical market. The
2.0 RESEARCH METHODOLOGY 2.1 Study Rationale U.S. has a lion s share in the global pharmaceutical market. The Federal government policy is to take care of the total health care cost of the U.S. citizens
More information2. Profile of pharmaceutical industry in India and Andhra Pradesh
2. Profile of pharmaceutical industry in India and Andhra Pradesh The first Indian pharmaceutical company, Bengal Chemicals and Pharmaceutical Works, which still exists today as one of 5 government-owned
More informationCHAPTER-IV COMMODITY COMPOSITION OF INDIAN FOREIGN TRADE DURING THE POST- WTO PERIOD
CHAPTER-IV COMMODITY COMPOSITION OF INDIAN FOREIGN TRADE DURING THE POST- WTO PERIOD The changes in the composition of trade in goods work as a mirror to watch the developments taking place in the domestic
More informationDraft NATIONAL PHARMACEUTICALS PRICING POLICY, 2011 (NPPP-2011) 1.1 The Indian pharmaceutical Industry, driven by knowledge, skills, low
Draft NATIONAL PHARMACEUTICALS PRICING POLICY, 2011 (NPPP-2011) 1. PREAMBLE AND BACKGROUND 1.1 The Indian pharmaceutical Industry, driven by knowledge, skills, low production costs and international quality
More informationEnforcement of Compliance with GMPs in API manufacture
Enforcement of Compliance with GMPs in API manufacture Guy Villax Copyright Hovione 2004 No one is more active in pharmaceutical ingredients Agenda What are APIs, GMP What is the legal framework What is
More informationCompany Research- Granules India Ltd [23/11/2017]
Summary Company Research- Granules India Ltd [23/11/2017] Company Overview- Granules is one of the large drug manufacturers in India. In last decade, the company has successfully moved up the pharma value
More informationLeading domestic players in India s pharmaceutical market in 2015
THE INDIAN PHARMACEUTICAL MARKET LEADING DOMESTIC COMPANIES 2015 Leading domestic players in India s pharmaceutical market in 2015 1 Executive Summary 1.1 Executive Summary 1.2 Research and Analysis Methods
More informationFrom Bench to Bedside. Russ H. Read June 23, 2014
From Bench to Bedside Russ H. Read June 23, 2014 Talent Required Scientists, clinicians, technicians, chemists, biologists, pharmacologists, toxicologists, research associates, regulatory experts, manufacturing
More information